Videos

What can we help you find?
Pharmacy Times® interviewed Chad Landmon, the chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, on the potential impact President-elect Joseph Biden’s cabinet nominations may have on the pharmacy field in 2021.
Although safety and efficacy have been proven, a few questions still remain about how long the vaccines will be effective and whether they prevent asymptomatic infection.
C. Difficile
Sources of transmission and challenges that impact the management of community-onset C. difficile.
 
Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on the rollout of phase 1b and c of COVID-19 vaccinations at Walgreens pharmacies.
CLL
Katie Culos, PharmD, BCOP and Daniel Wojenski, PharmD, BCPS, BCOP discuss the NCCN (National Comprehensive Cancer Center)-recommended front-line treatment options for patients with newly diagnosed CLL ([chronic lymphocytic leukemia)].
Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on whether any unforeseen problems have arisen during the first wave of COVID-19 vaccinations at long-term care facilities.
Pharmacy Times® interviewed Rina Shah, PharmD, group vice president of pharmacy operations and services at Walgreens, on the first wave of COVID-19 vaccine administration at long-term care facilities across the country.
C. Difficile
What health care providers need to know about the 2 strains of C. difficile, including types of patients impacted and typical outcomes.
NETs
Experts in the management of NETs discuss how the treatment landscape has evolved.
 
VTE
Paul Ament, PharmD, reviews the guidelines for the prevention of VTE.
Pharmacy Times® interviewed William von Oehsen, JD, principal at Powers Pyles Sutter & Verville, on a letter that was signed by President-elect Biden’s pick for HHS secretary to the outgoing HHS secretary on the enforcement of 340B drug pricing laws.
c. diff
Understanding the burden of C. difficile across the United States, panelists explore common risk factors associated with the condition and discuss the different ways it can manifest in patients.